Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Document › Details

AB Sciex (d/b/a Sciex). (9/22/15). "Press Release: Sciex Partners with the Paulovich Lab at Fred Hutchinson Cancer Research Center to Advance Cancer Research Reproducibility". Framingham, MA.

Organisations Organisation AB Sciex (Danaher, Framingham, MA)
  Group Danaher (Group)
  Organisation 2 Fred Hutchinson Cancer Research Center (Seattle, WA)
Products Product multiple reaction monitoring (MRM) technology
  Product 2 QTRAP® 6500+ LC-MS/MS System (Sciex)
Index term Index term Danaher–Fred Hutchinson: mass spectrometry, 201509– collab incl rights to commercialize the cancer immuno-MRM assays for Sciex
Persons Person Paulovich, Amanda (Fred Hutchinson 200412 Clinical Research Div)
  Person 2 Hunter, Christie (Danaher 201309 Director of Proteomics Applications at AB Sciex)

Collaboration Targets Research Reproducibility Crisis with Highly Validated Multiplex Quantitation Assays

SCIEX, a global leader in life science analytical technologies, today announced a collaboration with the laboratory of Amanda Paulovich, M.D., Ph.D., at Fred Hutchinson Cancer Research Center, to make Targeted Proteomics in cancer research more reproducible and specific. The collaboration provides SCIEX rights to commercialize the immuno-MRM assays that have been developed in the Paulovich Laboratory, a member of the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium. This effort, aligned with the National Institute of Health’s (NIH) strategy to make technology more widely accessible through public/private partnerships, will result in commercially available assays that quantitatively measure phosphorylated and unmodified proteins known to be involved in cancer signaling pathways.

Targeted Proteomics was named "Method of the Year" by Nature Methods in 2013, and Dr. Christie Hunter at SCIEX was awarded the Human Proteome Organization's 2013 Science and Technology Award for her contributions to the development and commercialization of this technology. To extend the reach of this technology, and make it more sensitive, and more routine and reproducible, an augmented approach is required over direct-MRM. Immuno-MRM assays combine the best features of immunoassays and mass spectrometry to provide highly reproducible, specific and sensitive quantification of target proteins, including phosphorylated proteins. However, a lack of availability of off-the-shelf content for this technique has been holding the field back, and this partnership aims to redress that.

By partnering with the Paulovich Laboratory, SCIEX will offer researchers a complete solution for mass spectrometry-based protein quantification of specific key biological pathways. At the HUPO 2015 Annual World Congress this week, SCIEX has introduced an improved targeted proteomics workflow that includes the new QTRAP 6500+ system and microflow LC, to combine high sensitivity and high throughput, and the Beckman Biomek Laboratory Automated Workstation, with optimized workflows for protein digestion. The immuno-MRM kits will be commercialized for this workflow, creating a solution that will include sample preparation reagents, antibodies and beads for target enrichment, internal standards for quantification, and related methods for LC-MS and data analysis.

"The research reproducibility crisis has been well-documented in the media recently, especially around antibody quality for immunoassays." said Aaron Hudson, Senior Director of Academic and Clinical Research Business at SCIEX. "This collaboration will help to address this crisis and extend our leadership in protein quantitation, by delivering highly validated protein assays for use on our best-in-class QTRAP systems."

"SCIEX has a long history in quantitative mass spectrometry, providing complete LC-MS solutions to scientists for biological research. We are very excited about this collaboration" said Paulovich, a Member in the Clinical Research Division at Fred Hutch. "Combined with the LC-MS systems from SCIEX, our immuno-MRM assays will enable academic and pharmaceutical researchers to rapidly generate high quality protein quantification results on target pathways."

This collaboration will produce highly validated off-the-shelf assays for running immuno-MRM experiments, which will improve biological reproducibility and thereby drive actionable research, which can be shared across labs.

As a key opinion leader and clinical researcher studying the molecular mechanisms of cancers for the purpose of developing novel therapies, Paulovich will receive the 2015 HUPO "Distinguished Achievement in Proteomic Sciences" award.

The immuno-MRM kits will be available in 2016.

For more information, visit SCIEX Proteomics Solutions

Fred Hutch does not endorse the use of any product referred to in this press release.


SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.

With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit

SCIEX social: Twitter, LinkedIn, and on Facebook.

For research use only. Not for use in diagnostic procedures. RUO-MKT-12-2606

AB Sciex is operating as SCIEX.

About Fred Hutchinson Cancer Research Center

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit or follow Fred Hutch on Facebook, Twitter or YouTube.

© 2015 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB Sciex™ is being used under license.

Contact Information

Stacey Sicurella
Public Relations and Brand Manager, Global Marketing

Editorial follow-up
Patrick Farrell
Sniper Public Relations on Behalf of SCIEX


Record changed: 2016-06-08


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

More documents for Danaher (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top